CREB Response (Gαs) | PLCβ3 Response (Gαq) | ||||||||
---|---|---|---|---|---|---|---|---|---|
logR (τ/KA) | ΔlogR (τ/KA)a | logR (τ/KA) | ΔlogR (τ/KA)a | ||||||
WIN | STHdhQ7/Q7 | 3.43 | (3.32–3.54)† | Reference ligand | 6.54 | (6.32–6.72) | Reference ligand | ||
STHdhQ111/Q111 | 2.22 | (2.20–2.24)^† | Reference ligand | 6.51 | (6.34–6.66) | Reference ligand | |||
CP | STHdhQ7/Q7 | 6.47 | (6.46–6.48)* | 3.01 | (2.91–3.11)*† | 5.77 | (5. 67–5.87)*† | −0.77 | (–0.92–0.62)*† |
STHdhQ111/Q111 | 5.07 | (5.06–5.08)* | 2.85 | (2.55–3.04)*† | 6.32 | (4.35–8.29)^ | −0.21 | (–0.48–0.06)^ | |
2-AG | STHdhQ7/Q7 | N.C. | N.C. | 6.01 | (4.66–7.36) | −0.53 | (–0.88–0.18)*† | ||
STHdhQ111/Q111 | N.C. | N.C. | 5.76 | (4.99–6.53) | −0.71 | (–1.46–0.04) | |||
AEA | STHdhQ7/Q7 | N.C. | N.C. | 6.31 | (6.08–6.54) | −0.23 | (–0.47–0.01) | ||
STHdhQ111/Q111 | N.C. | N.C. | 5.41 | (4.52–5.94)*^† | −1.13 | (–1.99–0.27)*† | |||
THC | STHdhQ7/Q7 | N.C. | N.C. | 5.45 | (5.23–5.67)*† | −1.09 | (–1.31–0.87)* | ||
STHdhQ111/Q111 | N.C. | N.C. | 4.33 | (3.80–4.86)*^† | −2.18 | (–2.69–1.67)*^ | |||
CBD | STHdhQ7/Q7 | 3.34 | (3.29–3.39) | −0.09 | (–0.22–0.04) | N.C. | N.C. | ||
STHdhQ111/Q111 | 2.27 | (2.24–2.30) | 0.03 | (–0.01–0.07) | N.C. | N.C. | |||
THC + CBD | STHdhQ7/Q7 | 0.26 | (–0.40–1.92)* | −3.19 | (–3.21–3.17)* | 0.57 | (–1.43–1.91)* | −5.97 | (–6.20–5.74)* |
STHdhQ111/Q111 | 3.28 | (3.27–3.30)*† | 1.06 | (1.04–1.08)*^† | 4.25 | (3.55–4.95)*^ | −2.27 | (–2.95–1.59)*^ |